STOCK TITAN

Xenetic Biosciences (XBIO) Form 4 Filings

XBIO NASDAQ

Here are the Form 4 insider transactions from Xenetic Biosciences, Inc. (XBIO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow XBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XBIO filings page.

Rhea-AI Summary

PARSLOW JAMES F reported acquisition or exercise transactions in this Form 4 filing.

Xenetic Biosciences, Inc. reported that Interim CEO and CFO James F. Parslow received a grant of 100,000 shares of Common Stock as a restricted stock grant. The award was made at a stated price of $0.00 per share, indicating compensation rather than a market purchase.

According to the vesting terms, 7,000 shares vest on the grant date, and one-third of the remaining 93,000 shares will vest on each of the first, second, and third anniversaries of April 21, 2026. Following this grant, Parslow directly holds 100,000 shares of Xenetic Biosciences common stock.